Spermosen’s team has a strong commitment to improving the quality of life for all those who live affected by infertility and involuntary childlessness. The mission is to support patients to achieve successful treatment by providing innovative diagnostic and treatment solutions for assisted reproduction.
Tore Duvold holds a PhD in bioorganic chemistry from Université Louis Pasteur, France. He is an experienced biotech entrepreneur and pharma executive with expertise in drug discovery, clinical development, CMC, regulatory affairs, business development and financing. His leadership spans multiple therapeutic areas, including inflammation, oncology, dermatology and cardiovascular disease. He has successfully launched companies, secured financing, and advanced drug candidates through clinical phases. Previously, Tore has held key positions including SVP and head of research, early development and patent at LEO Pharma, CEO and co-founder of Aker Biopharma, CEO of Coegin Pharma, CEO of Edvince and EVP and later CEO of Innovation Fund Denmark. He is also associated partner at Copenhagen Institute for Futures Studies.
CEO since: 2024
Holdings in Spermosens
Shares: 0
Options: 0
Alexander brings over 25 years of international finance and business delivery experience in large and category leading companies. His extensive background spans from smaller, growing organizations to large, well-established companies. Further his strong business-controlling and process development acumen will be a great asset for our expanding company. Alexander has in recent years worked as a freelance consultant supporting small and medium sized businesses.
CFO since: 2025
Maria Liljander holds a PhD in Reproductive Immunology from Lund University, Sweden. With over 20 years of experience at Lund University and Region Skåne, her research has primarily focused on complex genetics and immunology, particularly in relation to reproductive success and autoimmune diseases. Maria has more than 20 years of experience as a leader and researcher in several key roles at Region Skåne, Biobank Sweden, and the Lund Transgenic Core Facility. Throughout her career, she has fostered strong collaborations within academia and healthcare.
CSO since 2024
Holdings in Spermosens
Shares: 0
Options: 0
Jaime Castillo-León, a chemistry graduate from the Universidad Industrial de Santander (Colombia) and a Ph.D. in electrochemistry from Lund University (Sweden), is a professional with over 19 years of experience. His expertise lies in designing and fabricating electrochemical and optical biosensors and solar energy devices. He has held director and managerial positions in three Swedish and one Danish SMEs, focusing on biomedical and solar energy. He has also been an associate professor at DTU Nanotech, the Technical University of Denmark.
Panchami holds Masters in biotechnology from Amity University, Mumbai.
She has over 3+ years of experience in Recombinant DNA proteins, upstream and downstream processing of proteins.
Panchami has acquired experience in manufacturing and development of Invitro diagnostic kits and products.
She has held a challenging position of Management Representative as Quality Assurance head implementing ISO 13485 in the organization.
Chairman of the board
Board member since: 2024
Born: 1964
Holdings in Spermosens
–
Ulrik Spork has a strong background in institutional investments and has held positions as Managing Partner and Senior Partner at Novo Holdings. His responsibilities have included overseeing Principal Investments, Novo Growth Equity, and Novo Ventures. Since 2016, he has served as chairman of Danish Growth Capital II. In addition to venture investments, Ulrik also has extensive experience with SME boards in the medical technology and life science sectors and has over the last 30 years served as chairman or board member in more than 30 startup companies in jurisdictions across North America, Europe and Scandinavia.
Other ongoing significant assignments: Chairman in SoftOx Solutions AS, Innocon Medical ApS, board member in Cerebriu ApS.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Board member
Board member since: 2019
Born: 1967
Holdings in Spermosens
–
Dr. Ingela Liljeqvist Soltic is currently working as an embryologist and unit manager for the laboratory and tissue establishment at the Reproductive Medicine Center (RMC) at Skåne University Hospital. Ingela holds a BSc in Biomedical Laboratory Technology from Lund University and a PhD in Biomedical Science. She has previously worked as an embryologist at the IVF Clinic Cura Öresund and at the pharmaceutical company Merck. Ingela has extensive experience in IVF and fertility issues.
Other ongoing significant assignments: –
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Board member
Board member since: 2022
Born: 1961
Holdings in Spermosens
–
Christina Östberg Lloyd is currently the founder and CEO of Care & Communication AB, a consultant in Life Science with a focus on strategy and business management, leadership, communication, as well as medical and scientific affairs. She is also part of the management team at 2HealMedical, a healthcare company focused on women’s health, preconception, and infertility. Additionally, she serves as the chair of VILDA, a national network for women in top management within Life Science. Christina has 25 years of experience in big pharma, including roles at Ferring and Novo Nordisk, and was also the CEO of the femtech company Pharmiva, which was publicly listed under her leadership. Until recently, she was the global head at Ferring Pharmaceuticals A/S, serving as Senior Vice President and Global Head of Reproductive Medicine Maternal Health, RMMH. Christina is an M.D. and a specialist in gynecology and obstetrics, with a focus on reproductive medicine, covering both male and female infertility.
Other ongoing significant assignments: –
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Board member
Board member since: 2020
Born: 1976
Holdings in Spermosens (through company and privately)
Shares: 395 132
Søren Melsing Frederiksen currently holds the position of CEO at Exocure Sweden AB. Søren has a B.Sc. in Applied Science and a Master’s degree in Pharmaceutical Development. He was previously VP of Commercial & Product Development at Orifarm; VP of Sales & Marketing at Galenica AB; Head of Commercial at Aspen Nordic, and prior to that, he held several positions at LEO Pharma. Søren has extensive experience in product development, marketing, sales, and the entire value chain in the pharmaceutical industry.
Other ongoing significant assignments: Board member of VBM Ejendomsselskabet af 2007 Aps and StenoCare A/S. Board member and CEO of SML Holding ApS.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Board member
Board member since: 2018
Born: 1991
Holdings in Spermosens (through company and privately)
Shares: 1 637 764
Kushagr Punyani is the founder of the Company and served as a CSO consultant for the company until March 2024. Kushagr holds a Licentiate degree in Engineering, specializing in microfluidic technology, from Lund University. From his studies in India, together with Professor Sudha Srivastava, Kushagr laid the foundation for the Company’s technology. He has also co-founded several companies developing new technologies in the medtech/pharmaceutical sectors.
Other ongoing significant assignments: Board member of Prolevi Bio AB and Diagonal Bio AB. Board member and CEO of Nested Bio AB.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
The collaboration with OIM Sweden (OIM) gives Spermosen access to a high-quality as well as flexible ISO13485-certified production capacity with experience in MedTech products. This enables production ramp up to meet Spermosen’s global demand. Through flexible production capacity, both quality and cost efficiency are ensured.
OIM is one of Sweden’s most innovative product development companies, with a concept that combines technical competence with people, innovation, and business acumen. OIM develops products for companies through an innovative approach to product development.
OIM’s ability to deliver is based on many years of experience in running complex product development projects. This, combined with deep technical know-how, enables OIM to meet innovation and development in new ways.
We are very pleased to have the honor of partnering with Spermosens who are developing a ground-breaking product that facilitates a choice that many struggle with. The opportunity to work with products that make a difference to people’s everyday lives is close to OIM’s heart.
– Arash Golshenas – Co-founder of OIM Sweden
Read more at: oimsweden.com
FlexMedical Solutions (FMS) have been engaged to partner with Spermosens in transitioning the JUNO-Checked cassette into a safe, reliable, and cost effectively produced product to contribute to improved diagnosis and treatment of male infertility.
“Having worked closely with the team at Spermosens we have a high degree of confidence in their team, technology and vision, and believe our unique skill set will complement that of Spermosens’s, to ensure rapid productization and on-time delivery of the JUNO-Checked System”
– says Kevin Fallon, CEO of FlexMedical Solutions
The team at FMS has been developing and manufacturing diagnostic products over the last 3 decades, and having worked with some of the biggest players in global diagnostics, they are well placed to know how to leverage their experience, inhouse technology and knowhow to deliver the right solutions for clients on time.
For more information: www.flexmedical-solutions.com
Stefan has a broad interdisciplinary background from his undergraduate studies at the nanoengineering program, and subsequent PhD studies in Physics at Lund University, Sweden. Throughout his PhD he focused on the application of nano and microstructures for the analysis of particles, for the investigation of biological samples. In addition Stefan has an extensive knowledge about miniaturization of diagnostic devices for lab-on-chip applications.
The profound technical background has been a perfect match for Spermosens, and has been an instrumental component when Stefan and his colleagues at the renowned patent law firm HØIBERG, have developed a viable IP strategy on behalf of Spermosens. The Spermosens and HØIBERG teams work closely together to maintain and develop the patent portfolio of Spermosens.
Peter Holm is a European Patent Attorney, Partner and Country Manager for Sweden at the patent law firm HØIBERG. Together with Stefan Holm Nygaard, Peter is acting as Spermosens’ strategic IP advisor. Peter has a PhDin Biochemistry and Biophysics from Karolinska Institutet, Sweden and has been working as a patent attorney at HØIBERG since 2006, assisting startup companies and individual researchers within the lifescience field, with the development of their IP strategy.
Marisa has a broad and deep scientific background from her undergraduate studies at University of Pavía, Italy and her PhD studies at Lund University, where she worked on the development of a new technologies for treatment of textile wastewater. As a European Patent Attorney, Marisa has extensive experience in areas ranging from diagnostic medical devices to biological pharmaceuticals and novel foods. Her broad scientific and legal background is a valuable asset for the management of Spermosens’ advanced interdisciplinary technology.
Read more at: hoiberg.com
